{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:21:26Z","timestamp":1789662086426,"version":"4.0.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Our study aims to explore the pharmacokinetics of valproic acid (VPA) in Chinese patients with epilepsy or after neurosurgery and establish a robust population pharmacokinetics (PPK) model. The PPK model was developed using nonlinear mixed-effects modeling, incorporating a total of 615 VPA plasma concentration data points from 443 Chinese epilepsy or after neurosurgery patients. A one-compartment model with an additive residual model was established. Forward addition and backward elimination strategies were used to assess the impact of covariates on the model parameters. Goodness-of-fit plots, bootstrap, visual predict check and normalized prediction distribution errors were used for model validation. In the final model, the apparent clearance (CL) was estimated using the following formula: <jats:inline-formula><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"m1\"><mml:mrow><mml:mtext>CL\u2009<\/mml:mtext><mml:mrow><mml:mfenced open=\"(\" close=\")\" separators=\"|\"><mml:mrow><mml:mi mathvariant=\"normal\">L<\/mml:mi><mml:mo>\/<\/mml:mo><mml:mi mathvariant=\"normal\">h<\/mml:mi><\/mml:mrow><\/mml:mfenced><\/mml:mrow><mml:mo>=<\/mml:mo><mml:mn>0.430<\/mml:mn><mml:mo>\u00d7<\/mml:mo><mml:msup><mml:mrow><mml:mfenced open=\"(\" close=\")\" separators=\"|\"><mml:mrow><mml:mtext>BW<\/mml:mtext><mml:mo>\/<\/mml:mo><mml:mn>60<\/mml:mn><\/mml:mrow><\/mml:mfenced><\/mml:mrow><mml:mn>0.787<\/mml:mn><\/mml:msup><mml:mo>\u00d7<\/mml:mo><mml:msup><mml:mrow><mml:mfenced open=\"(\" close=\")\" separators=\"|\"><mml:mrow><mml:mtext>Cr<\/mml:mtext><mml:mo>\/<\/mml:mo><mml:mn>50.3<\/mml:mn><\/mml:mrow><\/mml:mfenced><\/mml:mrow><mml:mrow><mml:mo>\u2212<\/mml:mo><mml:mn>0.253<\/mml:mn><\/mml:mrow><\/mml:msup><mml:mo>\u00d7<\/mml:mo><mml:msup><mml:mrow><mml:mfenced open=\"(\" close=\")\" separators=\"|\"><mml:mrow><mml:mtext>ALB<\/mml:mtext><mml:mo>\/<\/mml:mo><mml:mn>39<\/mml:mn><\/mml:mrow><\/mml:mfenced><\/mml:mrow><mml:mrow><mml:mo>\u2212<\/mml:mo><mml:mn>0.873<\/mml:mn><\/mml:mrow><\/mml:msup><mml:mo>\u00d7<\/mml:mo><mml:msup><mml:mi mathvariant=\"normal\">e<\/mml:mi><mml:mtext>gender<\/mml:mtext><\/mml:msup><mml:mo>\u00d7<\/mml:mo><mml:msup><mml:mi mathvariant=\"normal\">e<\/mml:mi><mml:mtext>CBP<\/mml:mtext><\/mml:msup><mml:msup><mml:mrow><mml:mo>\u00d7<\/mml:mo><mml:msup><mml:mi mathvariant=\"normal\">e<\/mml:mi><mml:mrow><mml:mtext>IND<\/mml:mtext><mml:mn>2<\/mml:mn><mml:mtext>\u2009<\/mml:mtext><\/mml:mrow><\/mml:msup><mml:mo>\u00d7<\/mml:mo><mml:mi mathvariant=\"normal\">e<\/mml:mi><\/mml:mrow><mml:msub><mml:mi mathvariant=\"normal\">\u03b7<\/mml:mi><mml:mtext>CL<\/mml:mtext><\/mml:msub><\/mml:msup><\/mml:mrow><\/mml:math><\/jats:inline-formula> (gender = 0.121 when is female, otherwise = 0; CBP = 1.50 when combined with carbapenems, otherwise = 0; IND2 = 0.15 when combined with oxcarbazepine, carbamazepine, phenobarbital, or phenytoin, otherwise = 0). The volume of distribution (V<jats:sub>d<\/jats:sub>) was estimated using the formula: <jats:inline-formula><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"m2\"><mml:mrow><mml:mtext>Vd\u2009<\/mml:mtext><mml:mrow><mml:mfenced open=\"(\" close=\")\" separators=\"|\"><mml:mrow><mml:mi mathvariant=\"normal\">L<\/mml:mi><\/mml:mrow><\/mml:mfenced><\/mml:mrow><mml:mo>=<\/mml:mo><mml:mn>8.66<\/mml:mn><mml:mo>\u00d7<\/mml:mo><mml:msup><mml:mrow><mml:mfenced open=\"(\" close=\")\" separators=\"|\"><mml:mrow><mml:mtext>BW<\/mml:mtext><mml:mo>\/<\/mml:mo><mml:mn>60<\/mml:mn><\/mml:mrow><\/mml:mfenced><\/mml:mrow><mml:mn>0.751<\/mml:mn><\/mml:msup><\/mml:mrow><\/mml:math><\/jats:inline-formula>. Comedication with carbapenems could increase VPA clearance by 4.48 times, and comedication with oxcarbazepine could enhance VPA clearance by 116%. Besides, creatinine and albumin could affect VPA clearance. Goodness-of-fit plots, bootstrap, visual predict check and normalized prediction distribution showed acceptable data fit, stability, and predictability of the model. In our study, a PPK model was utilized to attain a more comprehensive insight into these variables, improving the accuracy and individualization of VPA therapy in Chinese patients with epilepsy or after neurosurgery.<\/jats:p>","DOI":"10.3389\/fphar.2024.1423411","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T04:39:01Z","timestamp":1731040741000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Combined carbapenem resulted in a 4.48-fold increase in valproic acid clearance: a population pharmacokinetic model in Chinese children and adults with epilepsy or after neurosurgery"],"prefix":"10.3389","volume":"15","author":[{"given":"Luofei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12883-015-0494-y","article-title":"The economic impact of epilepsy: a systematic review","volume":"15","author":"Allers","year":"2015","journal-title":"BMC Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s11096-019-00864-w","article-title":"Estimation of apparent clearance of valproic acid in adult Saudi patients","volume":"41","author":"Alqahtani","year":"2019","journal-title":"Int. J. Clin. pharm-net"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4212\/cjhp.v63i4.936","article-title":"Ertapenem-induced reduction in valproate levels: case report and review of the literature","volume":"63","author":"Bates","year":"2010","journal-title":"Can. J. Hosp. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/FTD.0b013e31811f3296","article-title":"Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents","volume":"29","author":"Birnbaum","year":"2007","journal-title":"Ther. drug Monit."},{"key":"B5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/archneur.1979.00500430023002","article-title":"Valproic acid: review of a new antiepileptic drug","volume":"36","author":"Bruni","year":"1979","journal-title":"Archives neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcrc.2020.12.005","article-title":"Interactions between carbapenems and valproic acid among the patients in the intensive care units","volume":"62","author":"Chen","year":"2021","journal-title":"J. Crit. Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics implications for drug therapy","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bdd.636","article-title":"Population pharmacokinetics of valproate in Mexican children with epilepsy","volume":"29","author":"Correa","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"B9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"284.e1","DOI":"10.1016\/j.ajem.2021.09.033","article-title":"Treatment of valproic acid overdose with meropenem in an epileptic patient","volume":"53","author":"Cunningham","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","article-title":"A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation","volume":"54","author":"Ding","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","article-title":"Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients","volume":"59","author":"Es","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/01.WNF.0000228209.69524.E8","article-title":"Therapeutic monitoring of valproate in psychiatry: how far have we progressed?","volume":"29","author":"Fleming","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Global","year":"2019","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/10600280211055508","article-title":"Valproic acid after neurosurgery induces elevated risk of liver injury: a prospective nested case-control study","volume":"56","author":"Guo","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e3236","DOI":"10.1136\/bmj.e3236","article-title":"Carbapenem antibiotics for serious infections","volume":"344","author":"Hawkey","year":"2012","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.kjms.2016.12.001","article-title":"Drug interaction between valproic acid and carbapenems in patients with epileptic seizures","volume":"33","author":"Huang","year":"2017","journal-title":"Kaohsiung J. Med. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","article-title":"Sex related differences on valproic acid pharmacokinetics after oral single dose","volume":"40","author":"Ibarra","year":"2013","journal-title":"J. Pharmacokinet. pharmacodynamics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.5414\/cpp48767","article-title":"Factors influencing valproate pharmacokinetics in children and adults","volume":"48","author":"Jankovic","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","article-title":"Population pharmacokinetics of valproate in Chinese children with epilepsy","volume":"28","author":"Jiang","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/11634080-000000000-00000","article-title":"Fundamentals of population pharmacokinetic modelling: modelling and software","volume":"51","author":"Kiang","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.21037\/apm-21-795","article-title":"Interaction between valproic acid and carbapenems: decreased plasma concentration of valproic acid and liver injury","volume":"10","author":"Li","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","article-title":"Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen","volume":"37","author":"Lin","year":"2015","journal-title":"Ther. drug Monit."},{"key":"B27","article-title":"Drugs effective in the therapy of the epilepsies. Goodman and Gilman's the pharmacological basis of herapeutics","author":"McNamara","year":"2001"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.clinthera.2017.04.005","article-title":"Population pharmacokinetics of valproic acid in patients with mania: implication for individualized dosing regimens","volume":"39","author":"Methaneethorn","year":"2017","journal-title":"Clin. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","article-title":"A systematic review of population pharmacokinetics of valproic acid","volume":"84","author":"Methaneethorn","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejpn.2014.12.010","article-title":"Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics?","volume":"19","author":"Miranda Herrero","year":"2015","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e111066","DOI":"10.1371\/journal.pone.0111066","article-title":"Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of \u03b3-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis","volume":"9","author":"Ogusu","year":"2014","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1365-2710.2002.00440.x","article-title":"Population pharmacokinetics of intravenous valproic acid in Korean patients","volume":"27","author":"Park","year":"2002","journal-title":"J. Clin. Pharm. Ther."},{"key":"B33","volume-title":"Oxcarbazepine, StatPearls, StatPearls publishing copyright \u00a9 2023","author":"Preuss","year":"2023"},{"key":"B34","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00228-018-2444-2","article-title":"A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy","volume":"74","author":"Rodrigues","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1037239","DOI":"10.3389\/fphar.2022.1037239","article-title":"Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: effect of ABCB1 gene polymorphism","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.14712\/23362936.2017.11","article-title":"Meropenem-induced valproic acid elimination: a case report of clinically relevant drug interaction","volume":"118","author":"\u0160\u00edma","year":"2017","journal-title":"Prague Med. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1345\/aph.1Q165","article-title":"No interaction between valproate and meropenem in a cirrhotic patient","volume":"45","author":"Spriet","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3109\/00498254.2015.1054002","article-title":"In vivo inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs","volume":"46","author":"Suzuki","year":"2016","journal-title":"Xenobiotica"},{"key":"B41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/pharmaceutics14040811","article-title":"Population pharmacokinetics of valproic acid in pediatric and adult caucasian patients","volume":"14","author":"Teixeira-da-Silva","year":"2022","journal-title":"Pharmaceutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0378-5173(01)00916-4","article-title":"Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers","volume":"233","author":"Torii","year":"2002","journal-title":"Int. J. Pharm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug\u2013drug interaction and patients\u2019 characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vu\u010di\u0107evi\u0107","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","article-title":"The effect of different carbapenem antibiotics (ertapenem, imipenem\/cilastatin, and meropenem) on serum valproic acid concentrations","volume":"38","author":"Wu","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"B45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejps.2018.06.033","article-title":"Population pharmacokinetics of valproic acid in epileptic children: effects of clinical and genetic factors","volume":"122","author":"Xu","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1023\/a:1013046229699","article-title":"Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits","volume":"18","author":"Yokogawa","year":"2001","journal-title":"Pharm. res-dordr"},{"key":"B47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2015","journal-title":"Epileptic Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00228-021-03246-2","article-title":"Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder","volume":"78","author":"Zang","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1423411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T04:39:07Z","timestamp":1731040747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1423411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1423411"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1423411","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"article-number":"1423411"}}